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well controlled by combination of IL-5Ra antibody and TNFa inhibitorDear Editor,
Benralizumab (Fasenra®) is a humanized, IL-5Ra-directed
monoclonal antibody that induces rapid and nearly complete
depletion of eosinophils, the dominating effector cells associated
with asthma. The inhibition of eosinophilic inflammation or
eosinophilia is expected to decrease airway injury, mucus hyperse-
cretion, and bronchial hyperresponsiveness.1,2 Golimumab (Sim-
poni®) is a fully humanized monoclonal antibody against TNF
-alpha (TNFa) that is administered once a month by subcutaneous
injection. In Japan, golimumab is approved as monotherapy and/or
in combination with methotrexate for the treatment of inflamma-
tory arthritis, including rheumatoid arthritis (RA), in adults.
Although strong evidence exists for the efficacy of these two ther-
apeutic monoclonal antibodies against these respective diseases,
almost no studies have been published on patients with these dis-
eases who were treated with the two biologics simultaneously.
Although treatment with a systemic steroid suppresses the activity
of both diseases, it is also associated with many complications. In
general, use of redundant immunosuppressive agents increases
the severity of associated complications (especially infectious dis-
eases). In contrast, most modern biologics act on specific factors
or mediators that are critical for the targeted disease or disorder,
and therefore, they are associated with fewer adverse effects than
are systemic steroids. We here report on a case of combined severe
eosinophilic asthma and refractory RA in which two biologics were
simultaneously used to achieve control of both diseases.
A 69-year-old man was referred to our hospital by his primary
physician. He had been diagnosed with allergic and eosinophilic
asthma and RA in his 40s. He gave us written informed consent
for publication of this case report. He was a previous smoker of
10e15 cigarettes a day for 18 years. He had no diagnosis of eosin-
ophilic granulomatosis with polyangiitis. The diagnosis of RA was
initially made on the basis of the presence of polyarthritis associ-
ated with autoantibodies such as rheumatoid factor (RF) and anti-
cylic citrullinated peptide antibodies (anti-CCP) and on the basis of
increased levels of CRP. At the time of diagnosis, his RA was stage
1; classification of the global functional status of his RA was class
3; and prednisolone, bucillamine, and salazosulfapyridine (SASP)
were started. The laboratory findings at the initial visit to our hos-
pital were as follows: white blood cell count, 6700/ml (eosinophils,Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).5.4% or 361/ml, max 600/ml); FeNO, 51 ppb; total IgE, 582 IU/ml;
and specific IgE positive for house dust, mite, and cedar pollen.
His forced vital capacity (FVC) was 72.2% of the predicted value;
FEV1, 49.8% of the predicted value; and FEV1/FVC ratio, 55.95%. Ac-
cording to the score-based algorithm of the 2010 ACR/EULAR clas-
sification criteria for RA, his total score for the 4 categories was 8/
10. His finger X-ray images taken at our hospital are shown in the
Supplementary Figure 1. His asthma had been treated with
inhalation therapy of ICS, LABA, and long acting muscarinic antag-
onist (LAMA). Just before visiting our hospital, when he was taking
7.5 mg of prednisolone every day, his CRP had gradually increased
to 5 mg/dl and his joint symptoms had deteriorated. We started
golimumab, which resulted in a rapid improvement in the joint
pain, and the systemic steroids were discontinued. Then, as a
nighttime asthmatic attack started to occur, we had to frequently
use short courses of systemic steroids. After stopping the golimu-
mab, we administered omalizumab, which was not effective. Then,
he responded well to benralizumab, with his asthma symptoms
improving remarkably, and the use of systemic steroids was dis-
continued. However, after 2 courses of benralizumab and the com-
plete discontinuation of the systemic steroids, a worsening of his
RA was observed. We stopped the benralizumab at this time, but
the asthma quickly worsened. Given that both diseases were
well controlled by use of the respective biologic agents, we
decided to start the concomitant use of therapeutic monoclonal
antibodies. Currently, 4 months have passed since the start of
the combination therapy, and both diseases are well controlled
without any prominent adverse effects. There is no need to
consider short induction therapy with systemic steroids. After 3
courses of benralizumab, the %FEV 1 was 80% and the FeNO was
31 ppb. The asthma control test (ACT) had also improved to 22
from 19 (Fig. 1).
Asthma is traditionally regarded as a chronic airway disease, and
recent studies have proven its heterogeneity on the basis of distinc-
tive clusters or phenotypes of asthma. A recent retrospective
population-based caseecontrol study showed that patients with
asthma had a significantly higher risk of developing RA than did
healthy individuals,3 suggesting the presence of a specific pheno-
type of severe asthma associated with RA.
In addition to IL-5, TNF-a is a proinflammatory cytokine that has
been implicated inmany aspects of the airway pathology of asthma.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Progress from visit to our hospital. SS, Additional administration of short courses of systemic steroids for treating acute asthma attacks; DAS 28-CRP(3), Disease Activity Score
3 variables (swollen joint, pain joint, CRP); ACT, Asthma Control Test. Left axis: Oral corticosteroids (OCS) (mg/day), CRP (mg/dl); Right axis: Eos (%).
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apoptosis via TNF-receptor 1, resulting in changes in the longevity
of human eosinophils.4 The effects of golimumab on severe asthma
have been the subject of several previous studies.5,6 Some of those
studies demonstrated an improvement in asthma quality of life,
lung function, and airway hyperresponsiveness and a reduction in
exacerbation frequency in patients treated with antieTNF-a ther-
apy. However, there was marked heterogeneity in the response,
suggesting that these benefits are likely reserved to a small
subgroup.7,8
Conversely, patients with RA had a 5-fold increase in serum
ECP values as compared with healthy individuals. High serum
ECP levels were particularly observed in patients with a disease
of rather short duration but with a more aggressive course.9
Furthermore, the treatment response of RA patients with mild
eosinophilia at diagnosis could be worse than that of those
without.10
Given the possibility that a synergistic effect may have been pro-
duced by combining anti-IL-5Ra and antieTNF-a therapies, this
case report could have important implications for asthma patients
with the specific phenotype associated with RA, potentially
enabling earlier disease recognition and opening the door to
improved treatments including combination therapy using
different biologic agents. Although, in this case, the possibility re-
mains that the biologic agent for RA itself induced exacerbation
of the asthma and vice versa, biologic combination therapies are
expected to be used in the future and their efficacy will be assessed
in larger studies.Acknowledgments
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